<SEC-DOCUMENT>0001193125-20-167242.txt : 20200612
<SEC-HEADER>0001193125-20-167242.hdr.sgml : 20200612
<ACCEPTANCE-DATETIME>20200612091632
ACCESSION NUMBER:		0001193125-20-167242
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200612
DATE AS OF CHANGE:		20200612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-238056
		FILM NUMBER:		20959052

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-792-6300

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d942797d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration Statement No. 333-238056 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">(To prospectus dated May&nbsp;18, 2020) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>$24,283,043 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942797g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">We have entered into an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales agreement, dated November&nbsp;8, 2017 with Stifel, Nicolaus&nbsp;&amp; Company, Incorporated (&#147;Stifel&#148; or the &#147;sales
agent&#148;) for the offer and sale of up to $30,000,000 of our shares of common stock, par value $0.00000002 per share, including the $24,283,043 of such shares (the &#147;Shares&#148;) offered by this prospectus supplement and the accompanying
prospectus. We previously sold $5,716,957 of our shares pursuant to such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales agreement under a separate registration statement. </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">In accordance with the terms of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales
agreement, we may offer and sell the Shares from time to time through the sales agent. Sales of the Shares, if any, under this prospectus may be made in sales deemed to be &#147;at the market offerings&#148; as defined in Rule 415 under the
Securities Act of 1933, as amended, or the Securities Act, including by means of ordinary brokers&#146; transactions on the Nasdaq Capital Market at market prices, in block transactions, or as otherwise agreed upon by the sales agent and us. The
sales agent will act as sales agent using commercially reasonable efforts to sell on our behalf all of the Shares requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent
and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. Under the terms of the sales agreement, we also may sell our Shares to Stifel, as principal for its own account at a price agreed upon at the time
of sale. If we sell shares to Stifel as principal, we will enter into a separate terms agreement setting forth the terms of such transaction, and we will describe the agreement in a separate prospectus supplement or pricing supplement. </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;MEIP.&#148; The last reported sale price of our common stock on the Nasdaq
Capital Market on June&nbsp;11, 2020 was $3.55 per share. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">The sales agent will receive from us a commission of up to 3% of the gross sales price per Share
sold through the sales agent under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales agreement. The sales agent is not required to sell any specific number or dollar amount of our
Shares, but, subject to the terms and conditions of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales agreement, the sales agent will use their commercially reasonable efforts to
sell on our behalf any Shares to be offered by us under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales agreement. See &#147;Plan of Distribution&#148; in this prospectus
supplement. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>An investment in our common stock involves significant risks. You should carefully consider the Risk&nbsp;Factors beginning on page&nbsp;13 of our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission on August&nbsp;28, 2019 and beginning on page 27 of our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the
fiscal quarter ended March&nbsp;31, 2020 filed with the Securities Exchange Commission on May&nbsp;5, 2020, and on page <FONT STYLE="white-space:nowrap">S-3</FONT> of this prospectus supplement before investing in our common stock. </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement and the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">The date of this prospectus supplement is June&nbsp;12, 2020. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_2">Cautionary Statement About Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-iii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_3">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_5">Use Of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_6">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_7">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_8">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_9">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc942797_10">Incorporation Of Certain Documents By Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_2">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_4">Cautionary Statement about Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_5">Securities Offered by this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_6">Use Of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_7">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_8">Description of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_9">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_10">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_11">Incorporation Of Certain Documents By Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_12">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference into this prospectus supplement and the accompanying base
prospectus and any free writing prospectuses prepared by us or on our behalf. We have not authorized any person to provide any information or make any statement that differs from what is contained in this prospectus supplement, the accompanying base
prospectus and any free writing prospectuses prepared by us or on our behalf. If any person does make a statement that differs from what is in this prospectus supplement, the accompanying base prospectus or any free writing prospectuses, you should
not rely on it. This prospectus supplement is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any jurisdiction in which the offer or sale is not permitted. You should assume that the information contained in
this prospectus supplement, the accompanying base prospectus, any free writing prospectus and the documents incorporated by reference is accurate only as of its respective date, regardless of the time of delivery of this prospectus supplement, the
accompanying base prospectus, any free writing prospectus or of any sale of shares of our common stock in this offering. Our business, financial condition, results of operations and prospects may have subsequently changed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying base prospectus are part of a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission, or SEC, using a &#147;shelf&#148; registration statement. Under the shelf registration statement, we may offer and sell any combination of
securities described in the accompanying base prospectus in one or more offerings. The accompanying base prospectus provides you with a general description of the securities we may offer. Each time we use the accompanying base prospectus to offer
securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in the accompanying base prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein include important information
about us, our common stock and other information you should know before investing. This prospectus supplement describes the specific details regarding this offering, including the price, the amount of common stock being offered and the risks of
investing in our common stock. The accompanying base prospectus provides general information about us, some of which may not apply to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">To the extent that any statement that we make in this prospectus supplement is inconsistent with statements made in the accompanying base
prospectus, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying base prospectus. You should read both this prospectus supplement and the accompanying base prospectus together with
additional information described under the heading, &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_2"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the documents incorporated by reference herein include forward-looking statements within the meaning
of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other than statements of historical
facts contained in this prospectus supplement and in the documents incorporated by reference herein, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are
forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and
similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe
may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in
&#147;Risk Factors&#148; and elsewhere in this prospectus supplement and the documents incorporated by reference herein, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and delays in our clinical development programs, including delays in patient enrollment relating to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and/or receipt of FDA or other required foreign and domestic governmental or regulatory approvals, or the failure to obtain such approvals, for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain required additional financing or financing available to us on acceptable terms, or at
all, whether as a result of weaknesses in the capital markets or otherwise, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kyowa Kirin Company (&#147;KKC&#148;), Helsinn Healthcare SA (&#147;Helsinn&#148;) and other parties with which
we have entered into collaboration, license, development and/or commercialization agreements may not satisfy their obligations under the agreements which could impact future revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations under the Presage Biosciences, Inc. License Agreement and the S*Bio Purchase Agreement,
which may reduce our cash available for other development efforts, and other obligations and risks related to the Presage License Agreement and the S*Bio Purchase Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies by their nature typically have a high level of risk and may not produce successful results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not
necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual
arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s interpretation and our interpretation of data from preclinical and clinical studies may differ
significantly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing regulations, third-party reimbursement practices and healthcare reform initiatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of any products to gain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials and manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to control the costs of manufacturing our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on acquisitions or licenses from third parties to expand our pipeline of drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition and competitive factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to operate our business without infringing the patents and proprietary rights of others;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs stemming from our defense against third party intellectual property infringement claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our exposure to potential product liability claims and other claims may exceed our insurance limits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulation generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in industry practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">one-time</FONT> events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this prospectus supplement and the documents incorporated by reference herein include
additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. There is substantial uncertainty regarding the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> on our business, industry, global economic conditions and government policy. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact
of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_3"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information appearing elsewhere or incorporated by reference in this prospectus supplement and
accompanying prospectus and may not contain all of the information that is important to you. This prospectus supplement and the accompanying prospectus include or incorporate by reference information about the shares we are offering as well as
information regarding our business, risks and detailed financial data. You should read this prospectus supplement and the accompanying prospectus in their entirety, including the information incorporated by reference. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are a
late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four
clinical-stage candidates, including one candidate in an ongoing Phase&nbsp;3 global registration trial and another candidate in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&#147;FDA&#148;) to
support accelerated approval of a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization
and strategic partnerships, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 11455 El Camino Real, Suite 250, San Diego, CA 92130, and our phone number is <FONT
STYLE="white-space:nowrap">(858)&nbsp;369-7100.</FONT> Our website is located at www.meipharma.com. Information on or accessible through our website is not part of, or incorporated by reference into, this prospectus supplement, other than documents
filed with the SEC that we incorporate by reference. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us pursuant to this prospectus supplement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Up to $24,283,043 of shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">We intend to use the net proceeds from the sale of Shares offered by this prospectus, together with other available funds, to progress our clinical development programs and for other general corporate purposes. See &#147;Use of
Proceeds&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-4.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;MEIP&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This investment involves a high degree of risk. See &#147;Risk Factors&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-3</FONT> of this prospectus supplement, the risk factors beginning on page 13 of our Annual
Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> filed with the Securities and Exchange Commission on August&nbsp;28, 2019 and beginning on page 27 of our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for
the fiscal quarter ended March&nbsp;31, 2020 filed with the Securities Exchange Commission on May&nbsp;5, 2020, as well as the other information included in or incorporated by reference in this prospectus supplement and the accompanying prospectus
for a discussion of risks you should consider carefully before making an investment decision.</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Any investment in our common stock involves a high degree of risk. In addition to the other information included or incorporated by
reference in this prospectus supplement and the accompanying prospectus, you should carefully consider the important factors set forth under the heading &#147;Risk Factors&#148; in our Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended June&nbsp;30, 2019, our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarter ended March&nbsp;31, 2020, and in our
subsequent annual reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> in other reports we file with the SEC from time to time, which are incorporated herein by reference, before investing in our securities. Any of the risk
factors referred to above could significantly and negatively affect our business, results of operations or financial condition, which may lower the trading price of our common stock. The risks referred to above are not the only ones that may exist.
Additional risks not currently known by us or that we deem immaterial may also impair our business operations. You may lose all or a part of your investment. For further details, see the sections entitled &#147;Where You Can Find More
Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Securities Markets and Investment in our
Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors in our Shares may experience significant dilution as a result of this and any future offerings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Because the sales of our Shares offered hereby will be made directly into the market or in negotiated transactions, the prices at which we
sell these Shares will vary and these variations may be significant. Purchasers of such Shares may suffer significant dilution if the price they pay is higher than the price paid by other purchasers of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion over the use of the net proceeds from this offering. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We will have broad discretion to use the net proceeds from the sale of Shares in this offering, and investors in our common stock will be
relying on the judgment of our board of directors and management regarding the application of these proceeds. Although we expect to use a substantial portion of the net proceeds from this offering for general corporate purposes and the progression
of our clinical trial programs, we have not allocated these net proceeds for specific purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of Shares offered by this prospectus, together with other available funds, to progress our
clinical development programs and for other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We have not specifically identified the precise amounts we will
spend on particular areas or the timing of these expenditures. The amounts actually expended for each purpose may vary significantly depending upon numerous factors, including the amount and timing of the proceeds from the sale of Shares offered by
this prospectus, the progress of our clinical trials and other product development activities. In addition, expenditures may also depend on the establishment of new collaborative arrangements with other partners, the availability of other financing
and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We anticipate that we will be required to raise substantial additional capital to continue to fund the clinical
development of our drug candidates. We expect to seek to raise additional capital through additional public or private financings, principally through equity issuances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We have entered into an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering sales
agreement, or &#147;sales agreement&#148; with Stifel, under which we may issue and sell from time to time up to $30,000,000 of our shares of common stock through the sales agent, including the $24,283,043 of Shares offered hereby. Sales of our
Shares, if any, under this prospectus may be made in sales deemed to be &#147;at the market offerings&#148; as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, including by means of ordinary brokers&#146;
transactions on the Nasdaq Capital Market at market prices, in block transactions, or as otherwise agreed upon by the sales agent and us. The sales agent will use commercially reasonable efforts to sell on our behalf all of the Shares requested to
be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The sales agent will not
engage in any transactions that stabilize our Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The sales agent will offer the Shares subject to the terms and conditions of the
sales agreement on any trading day or as otherwise agreed upon by us and the sales agent. We will designate the maximum amount and minimum price of Shares to be sold through the sales agent on a daily basis or otherwise determine such amounts
together with the sales agent. Subject to the terms and conditions of the sales agreement, the sales agent will use its commercially reasonable efforts to sell on our behalf the Shares. We may instruct the sales agent not to sell Shares if the sales
cannot be effected at or above the price designated by us in any such instruction. We or the sales agent may suspend the offering of Shares being made through the sales agent under the sales agreement upon proper notice to the other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The sales agent will receive from us a commission of up to 3% of the gross sales price per share for any Shares sold through it under the
sales agreement. The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for
the sale of such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The sales agent will provide written confirmation to us following the close of trading on the Nasdaq Capital
Market each day in which Shares are sold by the sales agent for us under the sales agreement. Each confirmation will include the number of Shares sold on that day, the gross sales price per Share, the net proceeds to us, and the compensation payable
by us to the sales agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Settlement for sales of Shares will occur, unless the parties agree otherwise, on the second business day that
is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Under the terms of
the sales agreement, we also may sell our Shares to the sales agent as principal for its own account at a price agreed upon at the time of sale. If we sell our Shares to the sales agent as principal, we will enter into a separate agreement setting
forth the terms of such transaction, and we will describe this agreement in a separate prospectus supplement or pricing supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In
connection with the sale of the Shares on our behalf, the sales agent may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation paid to the sales agent may be deemed to be underwriting commissions
or discounts. We have agreed in the sales agreement to provide indemnification and contribution to the sales agent against certain civil liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of the offering payable by us, excluding discounts and commissions payable to the sales agent under the
sales agreement, will be approximately $200,000, which amount includes up to $50,000 that we have agreed to reimburse Stifel for the fees and expenses of their counsel, including expenses previously paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The offering of Shares pursuant to the sales agreement will terminate upon the earlier of (1)&nbsp;the sale of all of the Shares subject to
the sales agreement and (2)&nbsp;the termination of the sales agreement by the sales agent or us. The sales agent has from time to time provided, and in the future may provide, certain commercial banking, investment banking and financial advisory
services to us and our affiliates, for which it has received, and in the future will receive, customary fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_7"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the securities offered hereby will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP, New York,
New York. Goodwin Procter LLP, New York, New York, is acting as counsel for the sales agent. Certain partners of Morgan, Lewis&nbsp;&amp; Bockius LLP own a number of shares of our common stock which represent less than 0.1% of the total outstanding
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The financial statements as of June&nbsp;30, 2019 and 2018, and for each of the three years in the period ended June&nbsp;30, 2019, and
management&#146;s assessment of the effectiveness of internal control over financial reporting as of June&nbsp;30, 2019, incorporated by reference in this prospectus supplement, have been so incorporated in reliance on the reports of BDO USA, LLP,
an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_9"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc942797_10"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus supplement the information we have filed with the SEC. The
information we incorporate by reference into this prospectus supplement is an important part of this prospectus supplement. Any statement in a document we incorporate by reference into this prospectus supplement or the accompanying prospectus will
be considered to be modified or superseded to the extent a statement contained in this prospectus supplement or any other subsequently filed document that is incorporated by reference into this prospectus supplement modifies or supersedes that
statement. The modified or superseded statement will not be considered to be a part of this prospectus supplement or accompanying prospectus, as applicable, except as modified or superseded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus supplement the information contained in the documents listed below, which is considered to be
a part of this prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519232454/d783135d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended June&nbsp;
30, 2019, as amended by the <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308275/d805454d10ka.htm">Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> </A>filed on December&nbsp;6, 2019; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519287262/d667344d10q.htm">September&nbsp;30,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520026751/d879582d10q.htm">December&nbsp;31, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520135561/d888492d10q.htm">March&nbsp;31,
2020</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519189160/d769812d8k.htm">July&nbsp;3,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308280/d842836d8k.htm">December&nbsp;
6, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519316554/d852426d8k.htm">December 18, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520080639/d898951d8k.htm">March 20, 2020</A>, the Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520105808/d891047d8k.htm">April&nbsp;14, 2020</A> with respect to Items 1.01, 1.02, and 9.01 and the
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520106585/d898635d8k.htm">April&nbsp;14, 2020</A> with respect to Items 5.02, 8.01 and 9.01;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in the Description of Capital Stock of MEI Pharma, Inc. filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308275/d805454dex43.htm">Exhibit
 4.3</A> to Amendment No.&nbsp;1 to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2019 and any further Description of Capital Stock of MEI Pharma, Inc. filed thereafter for the purpose
of updating such description. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference all documents filed pursuant to Sections 13(a), 13(c), 14
or 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination of this offering; provided, however, that we are not incorporating any information furnished under Item 2.02 or Item 7.01 of any current report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> we may subsequently file. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Statements made in this prospectus supplement or the
accompanying prospectus or in any document incorporated by reference in this prospectus supplement or the accompanying prospectus as to the contents of any contract or other document referred to herein or therein are not necessarily complete, and in
each instance reference is made to the copy of such contract or other document filed as an exhibit to the documents incorporated by reference, each such statement being qualified in all material respects by such reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">11455 El Camino
Real, Suite 250 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">San Diego, California 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Tel: <FONT STYLE="white-space:nowrap">(858)&nbsp;369-7100</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Attn: Investor Relations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Copies
of these filings are also available, without charge, through the &#147;Investors&#148; section of our website (www.meipharma.com) as soon as reasonably practicable after they are filed electronically with the SEC. The information contained on our
website is not a part of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942797g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer up
to $200,000,000 aggregate dollar amount of our common stock, preferred stock and warrants to purchase our common stock or preferred stock from time to time in one or more offerings. This prospectus provides you with a general description of the
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer these securities at prices and on terms to be set forth in one or more supplements to this prospectus. These
securities may be offered directly, through agents on our behalf or through underwriters or dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the
Nasdaq Capital Market under the symbol &#147;MEIP.&#148; On May&nbsp;18, 2020, the closing price of our common stock on the Nasdaq Capital Market was $2.94&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>An investment in our securities involves significant risks. See &#147;<A HREF="#toc942797_3">Risk Factors</A>&#148; on page&nbsp;3 of this
prospectus and in any applicable prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of factors you should carefully consider before deciding to purchase our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus
is May&nbsp;18, 2020. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_4">CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_5">SECURITIES OFFERED BY THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942797_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we have indicated otherwise, references in this prospectus to &#147;MEI Pharma,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; or similar terms are to MEI Pharma, Inc., a Delaware corporation. References in this prospectus to &#147;FDA&#148; refer to the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a
&#147;shelf&#148; registration statement. This prospectus provides you with a general description of the securities we may offer. We will describe the specific terms of those securities, as necessary, in supplements that we attach to this prospectus
for each offering. Each supplement will also contain specific information about the terms of the offering it describes. The supplements may also add to, update or change information contained in this prospectus. In addition, as we describe in the
sections entitled &#147;Incorporation of Certain Information by Reference&#148; and &#147;Where You Can Find More Information,&#148; we have filed and plan to continue to file other documents with the SEC that contain information about us. Before
you decide whether to invest in our securities, you should read this prospectus, the supplement that further describes the offering of those securities and the information we otherwise file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement that contains this prospectus, including the exhibits to the registration statement, contains additional
information about us and the securities being offered under this prospectus. You should read the registration statement and the accompanying exhibits for further information. The registration statement and exhibits can be read and are available to
the public over the Internet at the SEC&#146;s website at http: //www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or
incorporated by reference in this prospectus and in any prospectus supplement. We have not authorized any person to provide any information or make any statement that differs from what is contained in this prospectus. If any person does make a
statement that differs from what is in this prospectus, you should not rely on it. This prospectus is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any state in which the offer or sale is not permitted. The
information in this prospectus is accurate as of its date, but the information may change after that date. You should not assume that the information in this prospectus is accurate as of any date after its date. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a late-stage pharmaceutical company
focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage candidates,
including one candidate in an ongoing Phase 3 global registration trial and another candidate in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&#147;FDA&#148;) to support accelerated approval of
a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to building our pipeline
is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices
are located at 3611 Valley Centre Drive, Suite 500, San Diego, CA 92130, and our phone number is (858) <FONT STYLE="white-space:nowrap">369-7100.</FONT> </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any investment in our securities involves a high degree of risk. In addition to the other information included or incorporated by reference in
this prospectus and any accompanying prospectus supplement, you should carefully consider the important factors set forth under the heading &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
fiscal year ended June&nbsp;30, 2019, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020, and in our subsequent annual reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and
in other reports we file with the SEC from time to time, which are incorporated herein by reference, before investing in our securities. Any of the risk factors referred to above could significantly and negatively affect our business, results of
operations or financial condition, which may lower the trading price of our common stock. The risks referred to above are not the only ones that may exist. Additional risks not currently known by us or that we deem immaterial may also impair our
business operations. You may lose all or a part of your investment. For further details, see the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_4"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein include forward-looking statements within the meaning of Section&nbsp;27A
of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other than statements of historical facts contained in
this prospectus and in the documents incorporated by reference herein, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The
words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in &#147;Risk Factors&#148; and elsewhere
in this prospectus and the documents incorporated by reference herein, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and delays in our clinical development programs, including delays in patient enrollment relating to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and/or receipt of FDA or other required foreign and domestic governmental or regulatory approvals, or the failure to obtain such approvals, for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain required additional financing or financing available to us on acceptable terms, or at
all, whether as a result of weaknesses in the capital markets or otherwise, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kyowa Kirin Company (&#147;KKC&#148;), Helsinn Healthcare SA (&#147;Helsinn&#148;) and other parties with which
we have entered into collaboration, license, development and/or commercialization agreements may not satisfy their obligations under the agreements which could impact future revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations under the Presage Biosciences, Inc. License Agreement and the S*Bio Purchase Agreement,
which may reduce our cash available for other development efforts, and other obligations and risks related to the Presage License Agreement and the S*Bio Purchase Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies by their nature typically have a high level of risk and may not produce successful results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not
necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual
arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s interpretation and our interpretation of data from preclinical and clinical studies may differ
significantly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing regulations, third-party reimbursement practices and healthcare reform initiatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of any products to gain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials and manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to control the costs of manufacturing our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on acquisitions or licenses from third parties to expand our pipeline of drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition and competitive factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to operate our business without infringing the patents and proprietary rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs stemming from our defense against third party intellectual property infringement claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our exposure to potential product liability claims and other claims may exceed our insurance limits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulation generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in industry practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">one-time</FONT> events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this report and our other filings with the SEC include additional factors which could
adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. There is substantial uncertainty regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> on
our business, industry, global economic conditions and government policy. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent
to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_5"></A>SECURITIES OFFERED BY THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using this prospectus, we may offer from time to time, in one or more series, together or separately, at prices and terms to be determined at
the time of offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of common stock, $0.00000002 par value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of preferred stock, $0.01 par value; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warrants to purchase shares of common stock or preferred stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of preferred stock may be convertible into or exchangeable for shares of our
common stock or preferred stock issued by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Description of Securities&#148; for a description of the terms of the common
stock, preferred stock and warrants. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we expect to use a substantial portion of the net proceeds from the sale of securities under this prospectus for general corporate
purposes, including to progress our clinical trial programs, we have not allocated these net proceeds for specific purposes. If, as of the date of any prospectus supplement, we have identified any additional use for the net proceeds, we will
describe them in the prospectus supplement. The amount of securities offered from time to time pursuant to this prospectus and any prospectus supplement, and the precise amount of the net proceeds we will receive from the sale of such securities, as
well as the timing of receipt of those proceeds, will depend upon our funding requirements. If we elect at the time of an issuance of securities to make different or more specific uses of the proceeds than as set forth herein, we will describe those
uses in the applicable prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities included in this prospectus (i)&nbsp;through agents, (ii)&nbsp;through underwriters, (iii)&nbsp;through dealers,
(iv)&nbsp;directly to a limited number of purchasers or to a single purchaser, or (v)&nbsp;through a combination of any such methods of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more transactions, including block transactions and
transactions on the Nasdaq Capital Market or any other organized market where the securities may be traded: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or at final prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by us, or by agents designated by us, from time to time. Any such agent, which may be
deemed to be an underwriter as that term is defined in the Securities Act, as amended, involved in the offer or sale of the securities in respect of which this prospectus is delivered will be named, and any commissions payable by us to such agent
will be set forth, in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an underwriter is, or underwriters are, utilized in the offer and sale of
securities in respect of which this prospectus and the applicable prospectus supplement are delivered, we will execute an underwriting agreement with such underwriter(s) for the sale to it or them and the name(s) of the underwriter(s) and the terms
of the transaction, including any underwriting discounts and other items constituting compensation of the underwriters and dealers, if any, will be set forth in such prospectus supplement, which will be used by the underwriter(s) to make resales of
the securities in respect of which this prospectus and such prospectus supplement are delivered to the public. The securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more
transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be
changed from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect of which this prospectus is
delivered, we will sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. The name of the dealer and the terms of the
transaction will be identified in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an agent is used in an offering of securities being offered by
this prospectus, the agent will be named, and the terms of the agency will be described, in the applicable prospectus supplement relating to the offering. Unless otherwise indicated in the prospectus supplement, an agent will act on a best efforts
basis for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If indicated in the applicable prospectus supplement, we will authorize underwriters or their
other agents to solicit offers by certain institutional investors to purchase securities from us pursuant to contracts providing for payment and delivery at a future date. Institutional investors with which these contracts may be made include
commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and others. In all cases, these purchasers must be approved by us. The obligations of any purchaser under any of these
contracts will not be subject to any conditions except that (a)&nbsp;the purchase of the securities must not at the time of delivery be prohibited under the laws of any jurisdiction to which that purchaser is subject, and (b)&nbsp;if the securities
are also being sold to underwriters, we must have sold to these underwriters the securities not subject to delayed delivery. Underwriters and other agents will not have any responsibility in respect of the validity or performance of these contracts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters, dealers or agents utilized by us in any offering hereby may be customers of, including borrowers from,
engage in transactions with, and perform services for us or one or more of our affiliates in the ordinary course of business. Underwriters, dealers, agents and other persons may be entitled, under agreements which may be entered into with us, to
indemnification against certain civil liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the
securities is completed, rules of the SEC may limit the ability of the underwriters and certain selling group members, if any, to bid for and purchase the securities. As an exception to these rules, the representatives of the underwriters, if any,
are permitted to engage in certain transactions that stabilize the price of the securities. Such transactions may consist of bids or purchases for the purpose of pegging, fixing or maintaining the price of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters create a short position in the securities in connection with the offering thereof (in other words, if they sell more
securities than are set forth on the cover page of the applicable prospectus supplement), the representatives of such underwriters may reduce that short position by purchasing securities in the open market. Any such representatives also may elect to
reduce any short position by exercising all or part of any over-allotment option described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
such representatives also may impose a penalty bid on certain underwriters and selling group members. This means that if the representatives purchase securities in the open market to reduce the underwriters&#146; short position or to stabilize the
price of the securities, they may reclaim the amount of the selling concession from the underwriters and selling group members who sold those shares as part of the offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, purchases of a security for the purpose of stabilization or to reduce a syndicate short position could cause the price of the
security to be higher than it might otherwise be in the absence of such purchases. The imposition of a penalty bid might have an effect on the price of a security to the extent that it was to discourage resales of the security by purchasers in the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters, if any, makes any representation or prediction as to the direction or magnitude of any
effect that the transactions described above may have on the price of the securities. In addition, neither we nor any of the underwriters, if any, makes any representation that the representatives of the underwriters, if any, will engage in such
transactions or that such transactions, once commenced, will not be discontinued without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The anticipated date of delivery of the securities offered by this prospectus will be
described in the applicable prospectus supplement relating to the offering. The securities offered by this prospectus may or may not be listed on a national securities exchange or a foreign securities exchange. We cannot give any assurances that
there will be a market for any of the securities offered by this prospectus and any prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear costs relating to
all of the securities being registered under this prospectus, other than underwriters&#146; discounts and commissions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_8">
</A>DESCRIPTION OF SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Securities We May Offer Under this Prospectus </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our
common stock, please see the Description of Capital Stock of MEI Pharma, Inc. filed as Exhibit 4.3 to Amendment No.&nbsp;1 to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2019, filed
with the SEC on December&nbsp;6, 2019, and any future description of capital stock filed thereafter for the purpose of updating such description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material terms of
any series of preferred stock that we offer through a prospectus supplement will be described in that prospectus supplement. Our board of directors is authorized to provide for the issuance of blank check preferred stock in one or more series with
designations as may be stated in the resolution or resolutions providing for the issue of such preferred shares. At the time that any series of our preferred stock is authorized, our board of directors will fix the dividend rights, any conversion
rights, any voting rights, redemption provisions, liquidation preferences and any other rights, preferences, privileges and restrictions of that series, as well as the number of shares constituting that series and their designation. Our board of
directors could, without stockholder approval, cause us to issue preferred stock which has voting, conversion and other rights that could adversely affect the holders of our common stock or make it more difficult to effect a change in control. Our
preferred stock could be used to dilute the share ownership of persons seeking to obtain control of us and thereby hinder a possible takeover attempt which, if our stockholders were offered a premium over the market value of their shares, might be
viewed as being beneficial to our stockholders. In addition, our preferred stock could be issued with voting, conversion and other rights and preferences which would adversely affect the voting power and other rights of holders of our common stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to
purchase our common stock or preferred stock. Warrants may be issued independently or together with any other securities and may be attached to, or separate from, such securities. Each series of warrants will be issued under a separate warrant
agreement to be entered into between us and a warrant agent. The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe the following terms of any warrants in respect of which this prospectus is being delivered:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which such warrants will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies, in which the price of such warrants will be payable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securities purchasable upon exercise of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which and the currency or currencies in which the securities or other rights purchasable upon
exercise of such warrants may be purchased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise such warrants shall commence and the date on which such right shall
expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which such warrants are issued and the number of
such warrants issued with each such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which such warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of any material United States federal income tax considerations; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such warrants, including terms, procedures and limitations relating to the exchange and
exercise of such warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue 226,000,000 shares of common stock, par value $0.00000002 per share, and 100,000 shares of preferred stock, par
value $0.01 per share. As of May&nbsp;1, 2020, we had 105,998,677 shares of common stock outstanding and no shares of preferred stock outstanding. Also as of May&nbsp;1, 2020, we had outstanding (i) 11,159,988 shares of our common stock subject to
outstanding options, with exercise prices ranging from $1.21 to $6.47 per share, (ii) 16,061,602 shares of our common stock subject to outstanding warrants, with an exercise price of $2.54 per share, and (iii) 6,637,150 shares of our common stock
available for awards under our Amended and Restated 2008 Stock Omnibus Equity Compensation Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_9"></A>LEGAL
MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities described herein will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP, New York,
New York. Certain partners of Morgan, Lewis&nbsp;&amp; Bockius LLP own a number of shares of our common stock which represent less than 0.1% of the total outstanding common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of June&nbsp;30, 2019 and 2018, and for each of the three years in the period ended June&nbsp;30, 2019, and
management&#146;s assessment of the effectiveness of internal control over financial reporting as of June&nbsp;30, 2019, incorporated by reference in this Prospectus, have been so incorporated in reliance on the reports of BDO USA, LLP, an
independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus and any accompanying prospectus supplement the information we
have filed with the SEC. The information we incorporate by reference into this prospectus is an important part of this prospectus. Any statement in a document we incorporate by reference into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this prospectus will be considered to be modified or superseded to the extent a statement contained in this prospectus, any accompanying prospectus supplement or any other subsequently filed
document that is incorporated by reference into this prospectus or any accompanying prospectus supplement modifies or supersedes that statement. The modified or superseded statement will not be considered to be a part of this prospectus or any
accompanying prospectus supplement, as applicable, except as modified or superseded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus the
information contained in the documents listed below, which are considered to be a part of this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519232454/d783135d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended June&nbsp;30, 2019, as amended by the <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308275/d805454d10ka.htm"><FONT STYLE="white-space:nowrap">Form&nbsp;
10-K/A</FONT></A> filed on December&nbsp;6, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519287262/d667344d10q.htm">September&nbsp;30,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520026751/d879582d10q.htm">December&nbsp;31, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520135561/d888492d10q.htm">March&nbsp;31,
2020</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519189160/d769812d8k.htm">July&nbsp;3,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308280/d842836d8k.htm">December&nbsp;6, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519316554/d852426d8k.htm">December&nbsp;
18, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520080639/d898951d8k.htm">March&nbsp;
20, 2020</A>, the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520105808/d891047d8k.htm">April&nbsp;14, 2020</A> with respect to Items 1.01,
1.02, and 9.01 and the Current Report on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520106585/d898635d8k.htm">April&nbsp;14, 2020</A> with respect to Items 5.02, 8.01 and 9.01; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in the Description of Capital Stock of MEI Pharma, Inc. filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308275/d805454dex43.htm">Exhibit
 4.3</A> to Amendment No.&nbsp;1 to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2019 and any further Description of Capital Stock of MEI Pharma, Inc. filed thereafter for the purpose
of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference all documents filed pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after (i)&nbsp;the date of the initial registration statement and prior to the effectiveness of the registration statement and (ii)&nbsp;the date of this prospectus and prior to the termination of the offering of the
securities under this Registration Statement (except in each case for the information contained in such documents that is deemed to be &#147;furnished&#148; and not &#147;filed&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements made in this prospectus or any accompanying prospectus supplement or in any document incorporated by reference in this prospectus
or any accompanying prospectus supplement as to the contents of any contract or other document referred to herein or therein are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as
an exhibit to the documents incorporated by reference, each such statement being qualified in all material respects by such reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3611 Valley
Centre Drive, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San Diego, California 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tel: (858) <FONT STYLE="white-space:nowrap">792-6300</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn: Investor Relations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies
of these filings are also available, without charge, through the &#147;Investors&#148; section of our website (www.meipharma.com) as soon as reasonably practicable after they are filed electronically with the SEC. The information contained on our
website is not a part of this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942797_12"></A><A NAME="toc942797_12"></A><A NAME="toc942797_12"></A>WHERE YOU
CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC
filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file
electronically with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:63pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942797g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>$24,283,043 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%">&nbsp;</P></center>
<P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">June&nbsp;12,
2020 </P> <P STYLE="font-size:35pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g942797g63p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942797g63p02.jpg
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M(G9EWJVK[K<JUCJ-77UE23G/\?422#&>X!L#P&!QBE;.U16U=03EIJF>7/\
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M*K/$I7$D-N>,AQVI)!J9!%*D>5CC61A*C]=S6]13+%2Q/3R2+B>0L"5&/:6
MC?VCD:V"N!LH#'4)3<(\BO[J/<4BJJK]0^)!55?555,?OEY\_=?X^_[U]^UD
MY)&/0ES"/]%\W?&DJOW\%[4P;ERH/=V-?_J2<,7<O2>9C6_OW76N_P 0<O\
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M22@  BAQ':FOFJ.;%LSQTAME3%34M32FBI6[<2VF(M/),\35#50<AXJCM1)
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MCUP,QPH[&!?K/O4^>[81)3W6-?99135.!T=<F&1O[2EHR>@T1CJ>*8]-9_\
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M"F.+9DI3M))W@S=\:_U-I#T;1C?H;!!"JP@ZVM#%KZZO%'!  !'B$"""$B9
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E2TRB0#';R$RS'8@X=\Z,@X*QA%/>O$I^UHX*\+LN%PNRX7'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
